The stock trades on NXT-41x pipeline milestones, not current financials. Watch for FDA clearance of NXT-41 in Q4 2026 and any SimpliDerm/Cardiovascular divestiture announcements that could extend cash runway. The $8.0M escrow release in Q4 2026 is a near-term liquidity catalyst.
ELUT drugs
ELUT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 15 $1.03entry
- T+1 · 6mo ago +6.80%α +6.86% · $1.10
- T+5 · 6mo ago +12.62%α +11.66% · $1.16
- T+20 · 5mo ago −5.92%α −8.04% · $0.9690
- T+60 · 3mo ago −22.18%α −26.70% · $0.8015
Price Chart
How similar events traded
Executive Summary
Elutia reported Q1 2026 revenue of $3.1M (+6% YoY) and a GAAP net loss of $7.5M, widening from a $3.9M loss in Q1 2025, driven by a $6.7M non-cash swing in warrant liability revaluation. The core story remains the NXT-41x pipeline, with FDA clearance for NXT-41 on track for Q4 2026 and NXT-41x for 1H27, supported by a new automated manufacturing process targeting >80% gross margins at scale. The balance sheet is stable with $36.5M in cash and escrow, but the company is pre-revenue on its key catalyst and burning ~$4.4M in adjusted EBITDA per quarter.
Key Financial Metrics
Key Facts
- Q1 2026 net sales $3.1M, up 6% from $3.0M in Q1 2025
- GAAP net loss $7.5M vs $3.9M loss in Q1 2025, driven by non-cash warrant revaluation swing
- Adjusted EBITDA loss widened to $4.4M from $2.8M in Q1 2025
- Cash and escrow $36.5M ($28.5M cash + $8.0M escrow), expected to fund operations into 2027
- NXT-41 510(k) clearance on track for Q4 2026; NXT-41x clearance anticipated 1H27
- New automated manufacturing process installed, targeting >80% gross margins at scale
- Strategic processes for SimpliDerm and Cardiovascular product lines advancing
- 44.2M Class A shares outstanding plus 3.2M pre-funded warrants as of March 31, 2026
Financial Impact
Quarterly revenue $3.1M, net loss $7.5M, adjusted EBITDA loss $4.4M
Risk Factors
- FDA clearance delays for NXT-41 or NXT-41x
- Cash burn of ~$4.4M/quarter adjusted EBITDA could require additional financing before NXT-41x commercialization
- Dilution risk from 3.2M pre-funded warrants outstanding
- SimpliDerm and Cardiovascular revenue declining (SimpliDerm -19% YoY) as focus shifts to NXT-41x
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-061150 |
| Document: elut-20260514x8k.htm | 0001104659-26-061150 |
| Document: 0001104659-26-061150-index-headers.html | 0001104659-26-061150 |
| Document: 0001104659-26-061150-index.html | 0001104659-26-061150 |
| Document: 0001104659-26-061150.txt | 0001104659-26-061150 |
| 8-K Data (Synthetic) | 0001104659-26-061150 |
Track record
7 reports on ELUT
Filters
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $0.8374 Now $0.8230 −1.72% settles Dec 7
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $0.8615 Now $0.8230 −4.47% settles Nov 20
- Jul 31, 202615w ago Press Release Neutral 1/10 Entry $0.8568 to $0.8800 Now $0.8230 −3.94% ▲ +2.71% −0.28% vs SPY
- Jun 16, 202621w ago 8-K Neutral 3/10 Entry $0.9914 to $0.9500 Now $0.8230 −16.99% ▼ −4.18% −5.49% vs SPY
- May 14, 202626w ago 8-K Neutral 5/10 Viewing Entry $1.03 to $0.9690 Now $0.8230 −20.10% ▼ −5.92% −8.04% vs SPY
- Mar 11, 202635w ago 8-K Mixed 7/10 Entry $1.15 to $1.13 Now $0.8230 −28.43% ▼ −1.74% −3.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers